China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with the National Medical Products Administration (NMPA) for its anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) benmelstobart (TQB2450) in combination with the multi-target kinase inhibitor anlotinib. The targeted indication for this combination therapy is advanced alveolar soft tissue sarcoma (ASPS), which would mark the 12th indication for anlotinib and the 5th for benmelstobart if approved.
Understanding Advanced Alveolar Soft Tissue Sarcoma (ASPS)
ASPS is an extremely rare and highly malignant soft tissue sarcoma that accounts for 0.5% to 1% of all soft tissue sarcomas worldwide, with a global incidence rate of less than 1 per million. While more common in adolescents, ASPS is characterized by a slow disease course but poor prognosis, with a high tendency for early metastasis and diffusion, and is extremely insensitive to chemotherapy. The current treatment options are very limited, with a 5-year overall survival rate of only 20% to 46%, highlighting the urgent need for more effective treatment plans.
Potential Impact of the Benmelstobart and Anlotinib Combination Therapy
The filing for the combination therapy of benmelstobart and anlotinib represents a significant step forward in addressing the unmet medical needs of ASPS patients. If approved, this therapy could offer a new and potentially more effective treatment option, improving patient outcomes and survival rates.-Fineline Info & Tech
